STERIS plc STE

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived NYSE

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room ("OR") integration.

Last close 232.15 2026-10-23
Market cap $22.63B 2026-06-30 share count
52-week range 195.14 - 269.44

Valuation FY2025 figures against the last close

P/S3.8x
P/E29.3x
P/FCF23.3x
EV/EBITDA15.2x
Dividend yield1.1%
Diluted EPS7.93

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Other foreign locations
  • Ireland
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 4.3B (73.0%) 73% United States Other foreign locations, FY2025: 1.5B (25.2%) 25% Other foreign locations Ireland, FY2025: 108.5M (1.8%) FY2024 United States, FY2024: 4B (73.4%) 73% Other foreign locations, FY2024: 1.3B (24.6%) 25% Ireland, FY2024: 107.3M (2.0%) FY2023 United States, FY2023: 3.8B (73.0%) 73% Other foreign locations, FY2023: 1.3B (25.4%) 25% Ireland, FY2023: 82.7M (1.6%)
Region FY2025FY2024FY2023
United States $4.33B $4.01B $3.75B
Other foreign locations $1.49B $1.34B $1.30B
Ireland $108.5M $107.3M $82.7M

As the company reported it, from the “Business Segment Information - Revenues (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • Healthcare Segment
  • AST
  • Life Sciences
Revenue by segment, 3 categories over 3 years. The same figures are in the table below. FY2025 Healthcare Segment, FY2025: 4.2B (70.9%) 71% Healthcare Segment AST, FY2025: 1.1B (19.2%) 19% AST Life Sciences, FY2025: 588.8M (9.9%) 10% Life Sciences FY2024 Healthcare Segment, FY2024: 3.9B (71.0%) 71% AST, FY2024: 1B (19.0%) 19% Life Sciences, FY2024: 542.3M (9.9%) 10% FY2023 Healthcare Segment, FY2023: 3.6B (70.3%) 70% AST, FY2023: 954M (18.6%) 19% Life Sciences, FY2023: 571.7M (11.1%) 11%
Segment FY2025FY2024FY2023
Healthcare Segment $4.21B $3.88B $3.61B
AST $1.14B $1.04B $954.0M
Life Sciences $588.8M $542.3M $571.7M

As the company reported it, from the “Business Segment Information - Income Statement (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $5.94B$5.46B$5.14B$4.54B$4.22B$3.11B$3.03B$2.78B$2.62B$2.61B
Cost of revenue $3.31B$3.06B$2.92B$2.56B$2.34B$1.76B$1.71B$1.61B$1.53B$1.59B
Gross profit $2.63B$2.40B$2.22B$1.98B$1.88B$1.34B$1.32B$1.17B$1.09B$1.03B
R&D $112.9M$107.6M$103.7M$98.5M$86.7M$66.3M$65.5M$63.0M$60.8M$59.4M
SG&A $1.41B$1.33B$1.25B$1.09B$1.32B$731.3M$716.7M$669.9M$632.0M$682.0M
Total operating expenses $1.52B$1.54B$1.38B$1.19B$1.41B$794.7M$783.0M$764.0M$692.9M$800.0M
Operating income $1.10B$866.6M$836.1M$791.1M$477.8M$548.4M$537.0M$411.0M$399.9M$226.2M
Interest expense $60.7M$86.3M$144.4M$108.0M$89.5M$37.2M$40.3M$45.0M$50.6M$44.5M
Pre-tax income $1.05B$796.2M$702.8M$680.3M$366.8M$517.5M$498.8M$369.0M$355.0M$184.6M
Income tax $262.2M$184.7M$149.5M$124.1M$82.3M$120.7M$90.9M$64.3M$63.4M$74.0M
Net income $782.3M$614.6M$378.2M$107.0M$243.9M$397.4M$407.7M$303.7M$290.9M$110.0M
EPS, basic 7.976.243.831.072.504.664.813.593.421.29
EPS, diluted 7.936.203.811.072.484.634.763.553.391.28
Shares, diluted (wtd. avg.) 98.7M99.1M99.4M100.2M98.3M85.9M85.6M85.5M85.7M86.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $439.6M$171.7M$207.0M$208.4M$348.3M$220.5M$319.6M$220.6M$201.5M$282.9M
Receivables $1.09B$1.04B$1.01B$865.0M$799.0M$609.4M$586.5M$564.8M$528.1M—
Inventory $631.8M$581.3M$674.5M$604.4M$575.0M$315.1M$263.5M$208.2M$205.7M—
Total current assets $2.39B$2.00B$2.87B$2.01B$1.88B$1.21B$1.22B$1.05B$989.7M—
Property, plant and equipment $2.16B$1.96B$1.77B$1.63B$1.55B$1.24B$1.11B$1.03B$1.01B—
Goodwill $4.19B$4.10B$4.07B$3.88B$3.94B$3.03B$2.36B$2.32B$2.43B$2.23B
Other intangibles $1.62B$1.85B$2.12B$2.08B$3.33B$898.4M$565.5M$604.6M$727.0M—
Total assets $10.74B$10.15B$11.06B$10.82B$11.42B$6.57B$5.44B$5.07B$5.20B—
Accounts payable $338.8M$280.8M$251.7M$264.2M$225.7M$156.9M$149.3M$152.9M$135.9M—
Short-term debt $118.9M$125.0M$85.9M$60.0M$142.9M$0————
Total current liabilities $1.15B$1.02B$931.1M$861.8M$922.2M$577.9M$503.6M$465.2M$398.5M—
Long-term debt $1.81B$1.92B$3.12B$3.02B$2.95B$1.65B$1.15B$1.18B$1.32B—
Total liabilities $3.54B$3.53B$4.75B$4.73B$4.88B$2.68B$2.02B$1.89B$1.98B—
Retained earnings $3.02B$2.48B$2.09B$1.91B$2.00B$1.94B$1.66B$1.34B$1.15B—
Total equity $7.18B$6.60B$6.32B$6.09B$6.54B$3.89B$3.42B$3.20B$3.22B$2.81B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.34B$1.15B$973.3M$756.9M$684.8M$689.6M$590.6M$539.5M$457.6M$424.1M
Depreciation and amortisation $486.5M$476.2M$565.2M$552.9M$553.1M$219.2M$197.2M$225.9M$178.3M$188.1M
Stock-based compensation $61.7M$57.4M$56.5M$39.0M$57.7M$26.0M$23.8M$24.0M$22.2M$18.8M
Capital expenditure $369.0M$370.1M$360.3M$362.0M$287.6M$239.3M$214.5M$189.7M$165.5M$172.9M
Investing cash flow -$512.5M$388.8M-$887.4M-$383.3M-$666.6M-$1.15B-$319.7M-$213.2M-$203.8M-$104.3M
Financing cash flow -$568.2M-$1.57B-$85.2M-$498.7M$115.8M$345.6M-$163.1M-$294.8M-$356.2M-$267.1M
Dividends paid $241.8M$219.9M$200.6M$183.5M$163.2M$133.8M$123.0M$112.5M$102.9M$93.2M
Buybacks $235.5M$211.3M$11.8M$308.6M$55.8M$14.6M$51.2M$81.5M$65.5M$97.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-267599.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B Revenue, FY2016: 2.6B Gross profit, FY2016: 1B Net income, FY2016: 110M Revenue, FY2017: 2.6B Gross profit, FY2017: 1.1B Net income, FY2017: 290.9M Revenue, FY2018: 2.8B Gross profit, FY2018: 1.2B Net income, FY2018: 303.7M Revenue, FY2019: 3B Gross profit, FY2019: 1.3B Net income, FY2019: 407.7M Revenue, FY2020: 3.1B Gross profit, FY2020: 1.3B Net income, FY2020: 397.4M Revenue, FY2021: 4.2B Gross profit, FY2021: 1.9B Net income, FY2021: 243.9M Revenue, FY2022: 4.5B Gross profit, FY2022: 2B Net income, FY2022: 107M Revenue, FY2023: 5.1B Gross profit, FY2023: 2.2B Net income, FY2023: 378.2M Revenue, FY2024: 5.5B Gross profit, FY2024: 2.4B Net income, FY2024: 614.6M Revenue, FY2025: 5.9B Gross profit, FY2025: 2.6B Net income, FY2025: 782.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $2.61B $2.62B $2.78B $3.03B $3.11B $4.22B $4.54B $5.14B $5.46B $5.94B
Gross profit $1.03B $1.09B $1.17B $1.32B $1.34B $1.88B $1.98B $2.22B $2.40B $2.63B
Net income $110.0M $290.9M $303.7M $407.7M $397.4M $243.9M $107.0M $378.2M $614.6M $782.3M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.80B 27.8x 7.2%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%
ENOV Enovis CORP $1.22B — 6.7%